However, further experiments should be conducted in the future to examine the possibility of GJE and its bioactive compounds on the development of breast cancer in vivo, based on the fact that aromatase inhibitors are extensively used by post-menopausal women with estrogen-dependent breast cancer (Brueggemeier et al., 2005). This evidence concerns the gene CYP19A1 and breast cancer.